Key Takeaways
- Ruminant Biotech closed a $9.5M USD Series A round, co-led by Rosrain Investments and Cultivate Ventures, with participation from Marex and follow-on funding from AgriZeroNZ.
- The company is developing a long-duration methane mitigation solution tailored to pasture-based cattle systems.
- Initial regulatory approval is expected in New Zealand in early 2026, with Australia and New Zealand targeted for first commercial launch.
- Animal trials show the technology can reduce methane emissions by around 75% for 100 days with a single dose.
- The funding will accelerate regulatory pathways in Canada, Brazil, and the EU, support expanded market segments, and scale pilot manufacturing capacity.
Ruminant Biotech Secures Series A Funding to Commercialize Methane Reduction Technology
Ruminant Biotech, a New Zealand–founded agritech company developing a high-impact methane mitigation solution for pasture-based cattle, has announced the closing of a $9.5 million USD Series A investment round. The round was co-led by Rosrain Investments and Cultivate Ventures, with significant participation from global financial services platform Marex and follow-on investment from AgriZeroNZ.
Methane from ruminant livestock accounts for an estimated 6% of global human-caused greenhouse gas emissions, exceeding the combined emissions from aviation, shipping, and rail transport. Ruminant Biotech’s technology aims to directly address this challenge by offering a practical, scalable tool compatible with pasture-based systems—the dominant production model worldwide.
Funding to Support 2026 Launch and Global Regulatory Approvals
The new capital will support the company’s first commercial product launch in Australia and New Zealand in 2026, positioning it as the only high-efficacy, long-duration methane solution designed specifically for pasture-based cattle.
Funds will also be used to:
- Advance regulatory approvals in Canada, Brazil, and the EU
- Accelerate R&D to expand into new cattle segments
- Build capacity for scaled distribution and global market readiness
CEO Tom Breen said the investment strengthens the company’s commercial pathway.
“This investment positions us to commercialise our world-leading technology with a scalable business model that rewards on-farm emissions reductions through carbon markets. We’re excited to unlock new ways to reward farmers for reducing emissions, while helping industry and governments meet their climate goals.”
High-Impact, Long-Duration Methane Reduction
Early animal trials indicate that a single dose of Ruminant Biotech’s product can reduce methane emissions by around 75% for 100 days. The impact is significant: treating 100 steers could cut emissions equivalent to removing 50 family cars from the road for a full year.
Unlike feed additives, which require frequent dosing and are often limited to intensive farming systems, the company’s solution is designed for pasture-based operations—the majority of the world’s cattle. This opens a pathway for more than 550 global food and agriculture companies with Scope 3 climate commitments that currently lack scalable mitigation tools.
The company also plans to leverage carbon market mechanisms to reward farmers financially for verified methane reductions, offering new revenue streams that can stabilize farm incomes amid fluctuating commodity prices.
Industry and Investor Support Strengthens Ruminant Biotech Trajectory
Nigel Brunel, New Zealand Managing Director at Marex, highlighted the investment’s alignment with carbon market expansion.
“This investment is an exciting opportunity for Marex to gain further access to high-quality carbon credits which expand our range of products available to clients. We see significant potential in this investment for the future, and it strengthens our growing position as a provider for carbon credits for the region and globally.”
Ruminant Biotech has received strong public-sector support, with more than $11 million NZD in grants previously awarded to accelerate development and regulatory progress.
Wayne McNee, Chief Executive of AgriZeroNZ, added:
“AgriZeroNZ is investing in a range of tools to help farmers reduce emissions without compromising productivity or profitability. Ruminant Biotech’s solution is well suited for our pasture-based farms, having demonstrated long-lasting methane reduction in animal trials.”
Pilot Manufacturing Facility to Support Regional Supply
To prepare for commercial rollout, Ruminant Biotech has commissioned a multi-million-dollar pilot manufacturing facility in New Zealand. The site will produce up to one million doses annually for the Australian and New Zealand markets and will serve as a foundation for future scaling.
